Table 1 Demographics and clinical characteristics of patients treated with ONC201 who were evaluable for safety and efficacy

No. of Patients (%)

3 (15%)

17 (85%)

Male

2

8

Female

1

9

 ECOG = 0

2 (10%)

6 (30%)

 ECOG = 1

1 (5%)

11 (55%)

Age (years)^a

80 (42–92)

64 (35–79)

Weight (kg)^a

51.3 (50.4–55.0)

82.7 (56.4–109.1)

Doses^a

21 (18–30)

19.6 (4–70)

 Prior hormonal therapies^a

0

1.2 (1–6)

 Prior chemotherapies^a

2.3 (0–4)

2.2 (0–7)

 Prior immunotherapies^a

1 (0–2)

0.2 (0–1)

 Prior targeted therapies^a

0.7 (0–2)

0.8 (0–4)

Prior Radiation^a

1.5 (1–2)

1 (1–3)

Prior Surgery^a

2 (2–3)

3 (1–7)